Related references
Note: Only part of the references are listed.Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer
Gabriel Schmid et al.
BMC CANCER (2016)
Urokinase-type Plasminogen Activator (uPA) Promotes Angiogenesis by Attenuating Proline-rich Homeodomain Protein (PRH) Transcription Factor Activity and De-repressing Vascular Endothelial Growth Factor (VEGF) Receptor Expression
Victoria Stepanova et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Bmi-1 regulates stem cell-like properties of gastric cancer cells via modulating miRNAs
Xiaofeng Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Preclinical Activity of New [1,2]Oxazolo[5,4-e]isoindole Derivatives in Diffuse Malignant Peritoneal Mesothelioma
Virginia Spano et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts
Michelandrea De Cesare et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2016)
Combination therapy with bioengineered miR-34a prodrug and doxorubicin synergistically suppresses osteosarcoma growth
Yong Zhao et al.
BIOCHEMICAL PHARMACOLOGY (2015)
Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin
Michelandrea De Cesare et al.
Oncotarget (2015)
microRNA-34a as a Therapeutic Agent against Human Cancer
Yoshimasa Saito et al.
JOURNAL OF CLINICAL MEDICINE (2015)
Met inactivation by S-allylcysteine suppresses the migration and invasion of nasopharyngeal cancer cells induced by hepatocyte growth factor
Oyeon Cho et al.
RADIATION ONCOLOGY JOURNAL (2015)
Multipoint targeting of the PI3K/mTOR pathway in mesothelioma
S. Zhou et al.
BRITISH JOURNAL OF CANCER (2014)
Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells
Kinga Penzes et al.
CANCER BIOLOGY & THERAPY (2014)
Synergistic Antitumor Activity of Cetuximab and Namitecan in Human Squamous Cell Carcinoma Models Relies on Cooperative Inhibition of EGFR Expression and Depends on High EGFR Gene Copy Number
Michelandrea De Cesare et al.
CLINICAL CANCER RESEARCH (2014)
Cisplatin-induced epigenetic activation of miR-34a sensitizes bladder cancer cells to chemotherapy
Heng Li et al.
MOLECULAR CANCER (2014)
Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival
S. Ammoun et al.
ONCOGENE (2014)
MicroRNA-34a: a potential therapeutic target in human cancer
X. J. Li et al.
CELL DEATH & DISEASE (2014)
Mir-34: A New Weapon Against Cancer?
Gabriella Misso et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2014)
The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer
Douglas K. Graham et al.
NATURE REVIEWS CANCER (2014)
The Role of Perioperative Systemic Chemotherapy in Diffuse Malignant Peritoneal Mesothelioma Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Marcello Deraco et al.
ANNALS OF SURGICAL ONCOLOGY (2013)
Diffuse malignant peritoneal mesothelioma: Long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC)
Dario Baratti et al.
EUROPEAN JOURNAL OF CANCER (2013)
1p36 Tumor Suppression-A Matter of Dosage?
Kai-Oliver Henrich et al.
CANCER RESEARCH (2012)
AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy
M. V. Astle et al.
ONCOGENE (2012)
Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors
Dalia Ercan et al.
CANCER DISCOVERY (2012)
miR-34 – a microRNA replacement therapy is headed to the clinic
Andreas G. Bader
Frontiers in Genetics (2012)
Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-Mediated Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer
Ivan S. Donev et al.
CLINICAL CANCER RESEARCH (2011)
Coactivation of Receptor Tyrosine Kinases in Malignant Mesothelioma as a Rationale for Combination Targeted Therapy
Marie Brevet et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
An overview of the c-MET signaling pathway
Shawna Leslie Organ et al.
Therapeutic Advances in Medical Oncology (2011)
Efficacy of ST1968 (namitecan) on a topotecan-resistant squamous cell carcinoma
Valentina Zuco et al.
BIOCHEMICAL PHARMACOLOGY (2010)
ATM- and ATR-mediated response to DNA damage induced by a novel camptothecin, ST1968
Valentina Zuco et al.
CANCER LETTERS (2010)
The miR-34 family in cancer and apoptosis
H. Hermeking
CELL DEATH AND DIFFERENTIATION (2010)
Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma
Federica Perrone et al.
EUROPEAN JOURNAL OF CANCER (2010)
BCR-ABL-independent and RAS/MAPK pathway-dependent form of imatinib resistance in Ph-positive acute lymphoblastic leukemia cell line with activation of EphB4
Momoko Suzuki et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Maspin Regulates Endothelial Cell Adhesion and Migration through an Integrin Signaling Pathway
Li Qin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells
Na Li et al.
CANCER LETTERS (2009)
MicroRNA-34a Inhibits Glioblastoma Growth by Targeting Multiple Oncogenes
Yunqing Li et al.
CANCER RESEARCH (2009)
MicroRNAs: Target Recognition and Regulatory Functions
David P. Bartel
CELL (2009)
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience
Tristan D. Yan et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis
Y. Li et al.
ONCOGENE (2009)
Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells
Yasunori Fujita et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer
Dmitri Lodygin et al.
CELL CYCLE (2008)
A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts
Neelu Puri et al.
CANCER RESEARCH (2007)
Akt negatively regulates the in vitro lifespan of human endothelial cells via a p53/p21-dependent pathway
H Miyauchi et al.
EMBO JOURNAL (2004)
Maspin is an angiogenesis inhibitor
M Zhang et al.
NATURE MEDICINE (2000)
Share Paper
